Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research is to explore whether a pharmacist-led diabetes management program can help optimize diabetes care for older adults. Participation in this study will involve meeting with a pharmacist who works with subjects' doctors, getting some routine bloodwork typical for people with diabetes, and potentially adjusting the subject's diabetes medications to reach American Diabetes Association guidelines. This study aims to bring older adults with diabetes whose measurements and medications are different from the guidelines of the American Diabetes Association into guidelines-based ranges.
This study is a pragmatic pilot study assessing the feasibility and acceptability, and preliminary impact of a pharmacist-led care pathway to align patient care with guidelines for type 2 diabetes mellitus (T2DM) management in frail older adults, leveraging existing resources and pathways of care led by Clinical Prescribing Pharmacists. Eligible participants will be identified from the Electronic Health Record (EHR). Research staff will then approach the primary care physicians for identified patients to confirm that patients are appropriate for the intervention, as determined by the primary care physician (PCP). Patients will then be contacted both by letter and phone call, and invited to participate in the pharmacist-led pathway. Telephonic informed consent will be obtained. Outcomes for all participants will be accessed passively via the EHR. The study team hypothesizes that patients who go through the pharmacist-led primary care intervention will be more likely to have guideline-concordant medical therapy as compared with an EHR-based control group. Also, the study team believes that the intervention will reach at least 50% of those referred by their physicians to participate, the median number of outpatient visits will be three or less, and that the intervention will require a total of <3 hours for pharmacists and patients across the 3-month intervention period. In addition, the study team expects patients, physicians, and pharmacists will report the intervention is feasible, acceptable, appropriate, and high-value. Lastly, the study team believes that the intervention group will have a lower mortality than the comparison group.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | No Intervention | Subjects in this arm will receive standard of care treatment with no intervention. They will receive month 6 follow up. | |
| Active Decliners | No Intervention | Subjects who decline intervention. Standard of care treatment with month 6 follow up. | |
| Active Intervention | Experimental | Subjects are mailed Information about Type 2 Diabetes Mellitus (T2DM) Guidelines and Appointment Information (Face to face [F2F] or Telehealth). They attend up to 3 pharmacist visits, depending on if they reach target glucose levels. And they attend interviews. They also have month 6 follow up. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pharmacist-Led Optimization Intervention | Behavioral | Educational information mailed to participants and up to three pharmacist visits. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects who Achieve Glycosylated Hemoglobin (HbA1c) values | Proportion of subjects who achieve target value of HbA1c >7.5% | Month 6 |
| Change in HbA1c | From Baseline through Month 6 | |
| Random Glucose Measurements | The study team will track any glucose measurements obtained between initial enrollment and 6-12 months follow up after completion of the intervention, up until a total of 12 months after initial enrollment. This will be reported as a glucose trajectory. | From Baseline through Month 12 |
| Estimated Change in Out-of-Pocket Costs | Change in diabetes medication cost | From Baseline through Month 6 |
| Point estimates of Feasibility Measures: Participation/Reach | The proportion of those referred who chose to participate | Month 6 |
| Point estimates of Feasibility Measures: Number Contacted/Reach | Total number of subjects contacted | Month 6 |
| Point estimates of Feasibility Measures: Number at Risk/Reach | Total number of patients who meet inclusion/exclusion criteria at each site | Month 6 |
| Feasibility Measures: Effort Required to Enroll-Number Calls |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Emergency Department Visits and Hospitalizations | Using EHR and Patient Ping, the number of contacts with the Emergency Department (ED) and hospitals (composite) | Baseline through Month 18 |
| Number of Hypoglycemic Events Requiring Medical Assistance |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kathryn E. Callahan, MD | Atrium Health Wake Forest Baptist Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Atrium Health Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | United States |
Our study, "eFIcacious-Diabetes Care: a Pilot Study of a Pharmacist-Led Optimization Intervention to Achieve Guideline-based Care for Frail Older Adults" agrees to share study data that fulfill the International Committee of Medical Journal Editors (ICMJE) requirements starting after the first 3 months after our study has started and five years after our first article publication. We agree to provide data to researchers who can provide our lab with a methodologically sound proposal, and who need our data to help achieve aims outlined in their proposal. The study's data will be comprised of individual participant data that underlie the results reported in our publication. Participant data will be deidentified and can be used in text, tables, figures, and appendices, after approval from the study's primary investigator.
Beginning 3 mos and ending 5 years following article publication
The requests must include a proposal with clear aims as to why and how the data will be used. If proposal is approved, a data access agreement will need to be signed and will only be accessible for a 5-year period. All requests to gain access to the data will need to be sent to the study's PI, Kathryn Callahan, MD, MS, (kecallah@wakehealth.edu).
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Aug 25, 2022 | Jun 27, 2025 | ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Number of calls to enroll |
| Month 6 |
| Feasibility Measures: Effort Required to Enroll-Average Call Duration | Duration of calls to enroll in minutes. | Month 6 |
| Point estimates of Feasibility Measure-Number of Visits | Mean and median number of visits with the pharmacist before glucose levels are met. | Month 12 |
| Point estimates of Feasibility Measures: Time | Time until achieved medication goal per patient will be reported. An achieved medication goal is the following: HbA1c <8 while taking no sulfonylurea or insulin, or HbA1c between 7.5-8 on sulfonylurea or insulin (these would both meet guidelines-based care. | Month 12 |
Events defined as per action to control cardiovascular risk in diabetes (ACCORD) trial, as hypoglycemic episodes requiring hospitalization or care in an emergency department. |
| Time Frame: Baseline through Month 18 |
| Number of Injurious Falls | Identified by International Classification of Diseases-10th Revision (ICD-10) diagnostic codes; defined as per systolic blood pressure intervention trial (SPRINT) as falls requiring hospitalization or care in an emergency department. | Baseline through Month 18 |
| Mortality | Number of people who die as found in EHR and North Carolina (NC) death registry | Baseline through Month 18 |
| Implementation Metric--Feasibility | Feasibility (FIM): This is a questionnaire that helps determine feasibility of the intervention. Score ranges from 4-20, with a higher score meaning the participant feels the intervention is more feasible. | Baseline through Month 18 |
| Implementation Metric-- Acceptability | This is a questionnaire that helps determine acceptability of the intervention. Score ranges from 4-20, with a higher score meaning the participant feels the intervention is more acceptable. | Baseline through Month 18 |
| Implementation Metric-- Appropriateness | This is a questionnaire that helps determine appropriateness of the intervention. Score ranges from 4-20, with a higher score meaning the participant feels the intervention is more appropriate. | Baseline through Month 18 |
| Implementation Metric- Value | Three questions will be coded and analyzed through qualitative analysis. The study team will code comments by hand using content analysis and grounded theory. | Baseline through Month 18 |